Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu– positive advanced breast cancer: results of the CECOG LaVie trial

Christiane Thallinger¹,², Istvan Lang³, Cvetka Grasic Kuhar⁴, Rupert Bartsch¹, Christian F. Singer⁵, Lubos Petruzelka⁶, Bohuslav Melichar⁷, Regina Knittelfelder², Thomas Brodowicz¹,² and Christoph Zielinski¹,²*

Abstract

Background: Vinorelbine constitutes effective chemotherapy for metastatic breast cancer (MBC) and acts synergistically with trastuzumab in HER-2/neu positive disease. The present study was set out to evaluate the efficacy and safety of vinorelbine when combined with lapatinib, an anti-HER2 tyrosine-kinase inhibitor, as late-line regimen administered beyond previous disease progression on prior lapatinib in patients with HER-2/neu- positive MBC.

Methods: The CECOG LaVie study was designed as open-labeled, single-arm, multicenter phase II trial. Patients had to be pretreated with lapatinib plus chemotherapy, and received lapatinib at a daily dose of 1250 mg in combination with vinorelbine 20 mg/m² i.v. on days 1 and 8 of a three-week cycle until disease progression, intolerable toxicity or withdrawal of consent. Progression-free survival (PFS) was defined as primary study endpoint; secondary endpoints included overall survival (OS), response rate according to RECIST 1.1, and safety. The study was terminated early due to poor accrual.

Results: A total number of nine patients were included; lapatinib administered beyond disease progression combined with vinorelbine resulted in a median PFS of 7.7 months (95 % CI 0.56-14.91) and a median OS of 23.4 months (95 % CI 16.61 –30.13), respectively. Partial remission was seen in one of nine patients, three patients had stable disease of > six months, whereas the remaining five patients had primary disease progression. In two patients, modification of vinorelbine dose due to toxicity became necessary; no dose modification was needed for lapatinib. The majority of reported adverse events (AE) were grade 1 and 2 in severity with diarrhea being the most commonly observed AE.

Conclusion: In this heavily pretreated patient population, combination of vinorelbine plus lapatinib showed encouraging activity and was characterized by an acceptable safety profile. Despite the low patient number, lapatinib plus vinorelbine may constitute a potential treatment option in heavily pretreated patients with HER-2/neu-positive MBC previously exposed to lapatinib.

Trial registration: EudraCT number 2009-016826-15, (15. 10.2009)

Keywords: Metastatic Breast Cancer, HER-2/neu, Lapatinib, Vinorelbine, Chemotherapy
**Background**

Breast cancer is a heterogeneous disease encompassing distinct biological subtypes with distinct natural histories. The human epidermal growth factor receptor-2 (HER-2/neu) positive breast cancer subtype accounts for 10–15 % of all breast cancer cases. In the pre-trastuzumab-era, early-stage HER-2/neu positive disease had the second poorest prognosis after triple-negative breast cancer [1] thus leading to an accumulation of HER-2/neu positive breast cancers in the advanced disease setting [2, 3]. When highly expressed at membrane level, HER-2/neu undergoes hyperdimerization with itself or with other receptors of the erbB family thus activating various mitogenic pathways, specifically phosphatidylinositol 3-kinase (PI3K/AKT) and mitogen-activated kinase (MAPK) [4]. These pathways in terms induce continuous cell proliferation and new vasculature formation thus resulting in an aggressive phenotype with poor prognosis.

Trastuzumab, a monoclonal antibody targeting the HER-2/neu oncoprotein yields - in combination with various chemotherapies – significant and clinically relevant prolongation of progression-free survival (PFS) and overall survival (OS) as compared to chemotherapy alone. The varying interaction of trastuzumab with different chemotherapeutic drugs has been subject of various reports, which have indicated that such combination treatment might result in additive or even synergistic effects [5]. Of note, synergy was suggested for the combination of trastuzumab and vinorelbine, [6] which is popular due to its efficacy and ease of administration in conjunction with limited toxicity.

Despite high activity, resistance to trastuzumab will eventually occur during the course of treatment in metastatic HER-2/neu-positive disease, which has led to the development of various alternative anti-HER2 compounds including tyrosine-kinase inhibitors (TKIs) such as lapatinib and second-generation antibodies such as pertuzumab or T-DM1.

As member of the 4-anilinoquinazoline classes of kinase inhibitors, lapatinib reacts with the ATP binding site of EGFR, and HER2/neu thus resulting in inhibition of autophosphorylation and subsequent proliferative signaling [7]. Lapatinib is currently approved for the treatment of patients with HER-2/neu positive MBC who progressed on prior trastuzumab-based therapy or as first-line treatment in combination with letrozole in luminal B/HER-2/neu positive disease [8].

Treatment of MBC relies upon cascade-like sequential administration of cytotoxic compounds, thereby offering a chance for prolonged disease control [9–11]. In HER-2/neu positive breast cancer, a prolongation of PFS by the continuation of trastuzumab beyond progression under the proviso of a change of the hitherto administered cytotoxic drug was demonstrated (treatment in multiple-lines; TML) [12].

Vinorelbine constitutes effective chemotherapy for metastatic breast cancer (MBC) and acts synergistically with trastuzumab in HER-2/neu positive disease.

Based upon these considerations, it seemed reasonable to hypothesize that the combination of lapatinib plus vinorelbine could also result in significant anti-tumor activity in the challenging setting of late-line treatment in patients with HER-2/neu positive MBC pretreated with trastuzumab and lapatinib. Indeed, encouraging activity of lapatinib plus vinorelbine combination therapy has been already demonstrated in two phase II trials [13, 14] while the concept of lapatinib beyond disease progression was not investigated henceforth.

Thus, the objective of this phase II trial was to assess activity and safety of lapatinib plus vinorelbine in HER-2/neu positive patients with MBC who had progressed on previous lapatinib-based treatment.

**Methods**

**Study design**

This multicenter, open-labeled, single arm phase II trial included female HER-2/neu positive patients with MBC. Patients were enrolled between October 2010 and August 2012 from 7 sites in 4 countries.

All eligible patients with MBC were pretreated with lapatinib in combination with various cytotoxic drugs excluding vinorelbine. Lapatinib was administered beyond disease progression and prescribed at a dose of 1250 mg p.o. once daily on a continuous basis. Vinorelbine was administered at a dose of 20 mg/m² by intravenous infusion on days one and eight of a three-week cycle until disease progression or the necessity of discontinuation of study treatment due to unacceptable toxicity, withdrawal of consent, loss to follow up, or death.

The primary aim was to evaluate PFS in heavily pretreated MBC patients receiving the combination of lapatinib and vinorelbine with a descriptive intent only.

**Patient population**

Eligible patients were women ≥18 years of age with histologically or cytologically confirmed HER2/neu positive (HER2/neu 3+ as defined by immunohistochemistry and/or HER-2/neu gene amplification as defined by fluorescence in situ hybridization) MBC with at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v.1.1). Prior lapatinib-based treatment in first- or second-line therapy for metastatic disease was mandatory. Patients were required to have adequate organ and bone marrow function, Eastern Cooperative Oncology Group performance status of 0–1, life expectancy of more than 12 weeks and an adequate left ventricular ejection function of at least 50 % at baseline, as measured by either echocardiography or MUGA scan.
Exclusion criteria included concomitant endocrine therapy, previous radiotherapy for metastatic disease in order to allow for appropriate bone marrow reserve within frame of the current trial, active cardiac, hepatic or biliary disease and diseases or surgeries affecting gastrointestinal function. Patients undergoing concurrent treatment with anticancer or investigational agents, females pregnant or lactating, and those with a peripheral neuropathy of grade 2 or greater were also excluded. Any medication that was considered necessary for the patient’s welfare and was not expected to interfere with the evaluation of study treatment could be given at the discretion of the investigator. Other antitumor therapies were not permitted.

The study was approved by independent ethics committees and was conducted in accordance with the principles of the Declaration of Helsinki and the Note of Guidance on Good Clinical Practice. All patients provided written informed consent prior to study entry.

The study was approved by the following ethics committees: Ethikkommission des KH der Elisabethinen, Ethikkommission des Landes Salzburg, Ethikkommission der Medizinische Universität Wien, Etická komise FN Olomouc, Etická komise Všeobecní fakultní nemocnice, Medical Research Council Ethics Committee for Clinical Pharmacology, National Medical Ethics Committee of the Republic of Slovenia.

Study endpoints
Baseline tumor assessment (CT or MRI) of the chest, abdomen and brain were performed within 28 days before first study drug application and once every 6 weeks during treatment phase thereafter. Tumor response data were assessed by the investigator according to RECIST criteria v.1.1. Additionally, a bone scan was mandatory at baseline.

The primary endpoint was progression free survival (PFS), defined as the time from study entry until the first observation of disease progression according to the above schedule or death due to any cause. Secondary endpoints included overall survival (OS), defined as the time from study entry until death, objective response rate (ORR), defined as the percentage of patients experiencing confirmed complete response (CR) and partial response (PR) assessed by RECIST criteria v.1.1, and safety.

Safety and Tolerability
Safety parameters included adverse events (AEs) and serious AEs (SAEs), hematology and clinical chemistry, physical examination, periodic measurements of vital signs and electrocardiograms (ECGs) and evaluation of changes of left ventricular ejection fraction (LVEF). AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) and assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE version 4.0).

Statistical analysis
For this pilot study, sample size was not based on statistical considerations and therefore no formal sample-size calculation was conducted. A sample size of thirty patients was planned initially were considered to be appropriate for a phase II study in order to gain information on efficacy and safety of the study treatment in this setting. No interim analysis was planned. Study endpoints are provided above.

The study was closed due to slow accrual in April 2014 and data of the nine patients who were included into the study were analyzed. Descriptive statistical methods were used to summarize the study results.

Results
Patient characteristics
In total, nine female patients with locally recurrent, inoperable, or metastatic MBC were enrolled. All nine patients – representing the intention-to-treat (ITT) population – received at least one dose of study medication. Median patient age was 51.66 years (range 37–75 years). All patients were tested HER-2/neu positive by IHC or FISH analyses, and six patients had endocrine dependent disease (luminal B / Her2/neu; four patients had estrogen/progesterone receptor positive cancer, one patient estrogen receptor positive/progesterone receptor negative and one patient estrogen receptor negative/progesterone receptor positive).

Prior systemic treatment
All patients were heavily pretreated. Six patients had received anthracycline-based regimens in the neoadjuvant or adjuvant setting, whereas all patients had received prior capecitabine and seven taxanes (six patients docetaxel, one patient paclitaxel) for MBC.

One patient received prior lapatinib as third-line treatment for metastatic disease, which was not according to protocol.

Individual patients and treatment characteristics are given in Table 1.

Treatment exposure
In total, 74 cycles were delivered to 9 patients (range 2–19 cycles). Three patients showed remarkable long treatment duration and received 14, 15 and 19 treatment cycles, respectively. Lapatinib dose of 1250 mg/day was maintained in all patients without any dose reduction needed. Vinorelbine dose was reduced from 20 mg/m² to 12 mg/m² in two patients due to toxicity.
| Patient number | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
|----------------|---|---|---|---|---|---|---|---|---|
| **Menstrual status** | Premenopausal | Postmenopausal | Premenopausal | Premenopausal | Postmenopausal | Premenopausal | surgically sterilized | Postmenopausal | Premenopausal |
| **ECOG performance status** | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| **Hormone receptor status** (PR/ER) | PR pos/ER pos | PR pos/ER pos | negative | PR pos/ER pos | PR pos/ER pos | negative | negative | PR pos/ER neg | PR neg/ER pos |
| **Metastatic at initial diagnosis** | No | No | Yes | No | No | No | No | No | Yes |
| **Number of metastatic sites** | 4 | 5 | 1 | 2 | 1 | 3 | 1 | 2 | 1 |
| **Target lesions** | | | | | | | | | |
| **Non-target lesions** | 1 | 3 | 1 | 2 | 2 | 2 | 2 | 2 | 1 |
| **Site of metastatic disease** | Liver | Liver | Lung | Lung | Lung | Lymphnodes | Lung | Thoracic wall | Liver |
| **Prior neo-adjuvant treatment** | Yes | No | No | No | No | No | Yes | Yes | Yes |
| **Prior adjuvant treatment** | No | Yes | No | Yes | Yes | Yes | No | No | No |
| **Prior metastatic treatment** | | | | | | | | | |
| **Endocrine therapy** | first line | No | No | No | No | No | No | No | first line |
| **Chemotherapy** | second line | first/second/third line | first/second/third line | first/second line | first/second line | first/second line | first/second line | first/second/third line | first line |
| **Trastuzumab** | first line | first line | first line | first line | first line | first line | first line | first line | first line |
| **Lapatinib** | second line | second line | second line | second line | second line | second line | second line | second line | third line |
**Efficacy**

Over the study period, six out of nine patients had died due to disease progression or disease-related complications. Median PFS was 7.7 months (95% CI 0.56–14.91), and median OS 23.4 months (95% CI 16.61–30.13).

One patient experienced partial remission, three patients had stable disease over > six months, whereas the remaining five patients had disease progression at first restaging.

The three patients with longest treatment showed the longest PFS of 10.0, 12.8 and 14.6 months, respectively: Two of them had stable disease and one of them was the only partial responder on this study. No particular characteristics discerning these three patients from the others were identified.

**Safety**

In total, 117 adverse events have been reported in this study. The relationship to study drug was balanced between lapatinib and vinorelbine (18.8% related to lapatinib, 19.7% related to vinorelbine and 15.4% related to both). The majority of the reported adverse events (n = 105) were grade 1 and 2 in severity.

One patient experienced two grade 4 adverse events (hyperbilirubinemia and elevated level of GGT). For this patient, elevated liver enzymes have been described in the medical history at study entry and both grade 4 events considered to be unrelated to study treatment by the investigator.

One patient died due to grade 5 pulmonary embolisms, which was rated by investigator to be unrelated to study treatment.

Nine grade 3 adverse events were reported in 5 patients including neutropenia, diarrhea, hepatotoxicity, elevated levels of liver enzymes, hyponatremia, hypertension and humerus fracture.

Adverse events in this study were consistent with the known lapatinib and vinorelbine safety profiles.

Three serious adverse events have been reported (humerus fracture, pulmonary embolism and hypertension), all of them were considered unrelated to study treatment.

Most common adverse events are summarized in Table 2.

**Discussion**

Treatment of metastatic cancer is characterized by the onset of treatment resistance, which leads to tumor progression and ultimately to the patients’ death. To a degree, this course can be extended by the cascade-like use of different primarily efficacious, yet ultimately ineffective drugs. The spectrum of such drugs differs according to the molecular and biologic pattern of MBC. In patients with HER-2/neu positive MBC who are in the focus of the present report, available drugs include trastuzumab and lapatinib and, recently added, pertuzumab [15] and T-DM1 [16]. Of note, resistance to trastuzumab-based treatment can be partially overcome by maintaining trastuzumab beyond disease progression [12] while switching chemotherapy, which is known to interact with trastuzumab in a divergent manner according to the used substance [5]. Ultimately, however, activity of trastuzumab is lost requiring alternative treatment approaches. It was this widely therapy-resistant patient population with HER-2/neu positive tumors we had in mind when the present protocol for the LaVie study was designed. For this pilot study, sample size was not based on statistical considerations and therefore no formal sample-size calculation was conducted. In this study design trastuzumab- and lapatinib-pretreated patients with HER-2/neu positive MBC were planned to be treated with lapatinib beyond progression with the addition of vinorelbine. The latter compound was chosen as chemotherapy backbone due to first, its previously described synergistic activity with trastuzumab [6] and second, the fact that many patients with HER-2/neu positive disease would be ultimately treated with lapatinib and capecitabine [17] without any evidence-based further treatment option.

With encouraging results from phase I trials testing for the combination of lapatinib and vinorelbine available [18, 19], the present data in a heavily pretreated patient population show that lapatinib plus vinorelbine constitutes another safe and moderately efficacious treatment option for HER-2/neu positive MBC. The trial was terminated due to poor recruitment, which can be explained by its design, which foresaw the inclusion of patients with very late line of treatment. The problem is reflected well by the fact that six out of nine patients died during the study period due to progression of their respective disease or to disease-

**Table 2** Most common adverse events

|               | Grade 1/2 n (%) | Grade 3 n (%) | Grade 4 n (%) | Total n (%) |
|---------------|-----------------|---------------|---------------|-------------|
| Diarrhea      | 20 (17.1)       | 1 (0.9)       | 0 (0)         | 21 (17.9)   |
| Neutropenia   | 9 (7.7)         | 1 (0.9)       | 0 (0)         | 10 (8.5)    |
| Leucopenia    | 8 (6.8)         | 0 (0)         | 0 (0)         | 8 (6.8)     |
| Increased alkaline phosphatase | 3 (2.6) | 1 (0.9) | 0 (0) | 4 (3.4) |
| Nausea        | 4 (3.4)         | 0 (0)         | 0 (0)         | 4 (3.4)     |
| Fatigue       | 4 (3.4)         | 0 (0)         | 0 (0)         | 4 (3.4)     |
related complications. Thus, the data obtained in this small population of patients have to be interpreted with caution. Nevertheless, even in this heavily pretreated population at late disease stage, the combination of lapatinib and vinorelbine resulted in a median PFS of 7.7 months (95 % CI 0.56–14.91) and a clinical benefit in four out of nine patients with HER-2/neu MBC who had either partial remission (one patient) or stable disease of > six months duration (three patients). Of note, results with regards to PFS are similar to PFS data from the lapatinib registration trial; in this prospective randomized phase III trial, the combination of lapatinib plus capecitabine yielded 8.4 months median PFS [17]. Thus, our results indicate that lapatinib-based therapy beyond disease progression may be feasible in a population of women with MBC who had received both, lapatinib and capecitabine previously.

Although naturally limited by the small number of patients accrued, data from the present study indicate that similar to trastuzumab, administration of lapatinib in multiple-lines may constitute a meaningful treatment option in selected patients and vinorelbine is valuable cytotoxic combination partner for lapatinib. Since the initiation of the LaVie trial, several novel anti-HER2 agents became available. It is therefore unlikely that the concept of lapatinib-based treatment in multiple lines will be investigated in larger studies. Therefore, and with all caution due to the mentioned limitations, we believe that results of LaVie add knowledge to the field or therapy of HER2/neu metastatic breast cancer.

**Conclusion**

The present study was set out to evaluate the efficacy and safety of vinorelbine when combined with lapatinib, an anti-HER2 tyrosine-kinase inhibitor, as late-line regimen administered beyond previous disease progression on prior lapatinib in patients with HER-2/neu positive MBC. In this heavily pretreated patient breast cancer population, combination of vinorelbine plus lapatinib showed encouraging activity and was characterized by an acceptable safety profile. Despite the low patient number, lapatinib plus vinorelbine may constitute a potential treatment option in heavily pretreated patients with HER-2/neu positive MBC previously exposed to lapatinib.

**Competing interests**

CZ has received advisory board honoraria from Roche and GSK, TB has received lecture fee from GSK; RB received lecture honoraria and travel support from GSK, Roche and Pierre-Fabre; MB received honoraria for speech and advisory role from Roche, GSK and Novartis.

**Authors’ contribution**

CT and RK wrote the manuscript and managed and analyzed the data, CT, RB, RK, TB and CZ made substantial contributions to the concept and design. IL, CK, LP and BH revised the manuscript critically. IL, CK, RB, CS, LP and BH coordinated the study with responsibility of the trial on their sites.

All authors have read and approved all versions of the letter, its content, and its submission to your Journal.

**Acknowledgement**

The LaVie trial was sponsored by the Central European Cooperative Oncology Group (CECOG). The study was made possible by financial support from Glaxo Smith Kline. The ideas and opinions expressed herein are those of the authors. Glaxo Smith Kline had no role in the collection, analysis and interpretation of the data, as well as in the writing of this manuscript.

**Author details**

1. Department of Medicine I and Comprehensive Cancer Center, Clinical Division of Oncology, Medical University Vienna – General Hospital, Währinger Gürtel 18-20, 1090 Vienna, Austria. 2. Central European Cooperative Oncology Group (CECOG), Schlagergasse 6/6, 1090 Vienna, Austria. 3. National Institute of Oncology, Ráth György u. 7-9, H-1122 Budapest, Hungary. 4. Medical Oncology Department, Institute of Oncology Ljubljana, Zaloska 2, 1000 Ljubljana, Slovenia. 5. Division of Gynecological Oncology, Währinger Gürtel 18-20, 1090 Vienna, Austria. 6. Department of Oncology, Charles University Prague, U nemocnice 2, 12808 Prague, Czech Republic. 7. Department of Oncology, Palacky University Medical School and Teaching Hospital, I.P. Pavlova 6, 77520 Olomouc, Czech Republic.

Received: 5 April 2015 Accepted: 14 February 2016

**References**

1. Aviara A, Dirix L, Manso Sanchez L, Xu B, Luu T, Dieras V, et al. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol. 2013;24(1):109–16.

2. Lund MJ, Butler EN, Hair BY, Ward KC, Andrews JH, Oprea-Ilies G, et al. Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report. Cancer. 2010;116(1):2549–59.

3. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341–54.

4. Yakes FM, Chirntranalab W, Ritter CA, King W, Seelig S, Apte AG. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002;62(14):4132–41.

5. Pegram MD, Koncny GE, O’Callaghan C, Bent M, Petras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst. 2004;96(10):739–49.

6. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001;19(10):2722–30.

7. Shewchuk L, Hassell A, Wilsely B, Rocque W, Holmes W, Veal J, et al. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. J Med Chem. 2000;43(1):133–8.

8. Spector NL, Xia W, Burris 3rd H, Hurwitz H, Dees EC, Dowlati A, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol. 2005;23(11):2502–12.

9. Andre F, Zieliński CC. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol. 2012;23 Suppl 6:v146–51.

10. Beslja S, Bonneteau J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2009;20(11):1771–85.

11. Cardoso F, Costa A, Norton L, Senkus E, Aapro M, Andre F, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)agger. Ann Oncol. 2014;25(10):1871–88.

12. von Minckwitz G, du Bois A, Schmidt M, Maas N, Cuen T, de Jongh FE, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03–05 study. J Clin Oncol. 2009;27(12):1999–2006.

13. Chan A, Shannon C, de Boer R, Baron-Hay S, Redfearn A, Bauwens A, et al. Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer. Asia Pac J Clin Oncol. 2014;10(4):368–75.
14. Janni W, Sarosiek T, Karaszewska B, Pikiel J, Staroslawski E, Potemski P, et al. A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2014;143(3):493–505.
15. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–19.
16. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91.
17. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–43.
18. Chew HK, Somlo G, Mack PC, Gitlitz B, Gandour-Edwards R, Christensen S, et al. Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors. Ann Oncol. 2012;23(4):1023–9.
19. Brain E, Isambert N, Dalenc F, Dieras V, Bonneteau J, Rezai K, et al. Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2. Br J Cancer. 2012;106(4):673–7.